In the future, we expect that additional biomarkers will distinguish indolent Barrett's oesophagus from Barrett's oesophagus at high risk of progression, so that many patients can be followed up with the Cytosponge-TFF3 procedure, and endoscopy can be reserved for those at a high risk who are likely to require intervention. Here, TFF3 is linked to Barrett esophagus.